Recently Approved Drugs: Blinatumomab for B-cell precursor ALL

Alex Ganetsky, PharmD, BCOP, oncology clinical pharmacy specialist at the Hospital of the University of Pennsylvania in Philadelphia discusses the approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.